Novo Nordisks product information states that semaglutide in its Wegovy form is FDA-approved for chronic weight management in adults with a BMI of 30 or greaterand it can also be prescribed to those with a BMI of 27 or greater who also have weight-related medical problems
These changes typically resolve within 23 months as the body adapts to both the drug and the new weight set point, though individual timelines vary
Although higher muscle mass can protect against muscle cramps [14], our study found no association between baseline BMI and cramp frequency and severity
These results support a more integrated, medical approach to weight and risk factor management in AF while also highlighting the need for prospective randomized trials before definitive changes in practice are made. For more information: Rutvij Patel, MD, can be reached at [email protected].
Oper Res 71(4):12981317 Leao AA, Toledo FM, Oliveira JF, Carravilla MA, Alvarez-Valds R (2020) Irregular packing problems: a review of mathematical models